



This is a repository copy of *A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/199599/>

Version: Published Version

Article:

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). *Rheumatology*, 62 (9). pp. 3133-3138. ISSN 1462-0324

<https://doi.org/10.1093/rheumatology/kead012>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown






If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Clinical science

A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)

Deborah J. Griffiths-Jones¹, Yvonne Sylvestre Garcia², W. David Ryder², John D. Pauling ³, Frances Hall⁴, Peter Lanyon⁵, Smita Bhat⁶, Karen Douglas⁷, Harsha Gunawardena⁸, Mohammed Akil⁹, Marina Anderson¹⁰, Bridget Griffiths¹¹, Francesco Del Galdo ¹², Hazem Youssef¹³, Rajan Madhok¹⁴, Barbara Arthurs¹, Maya Buch ^{1,15}, Kim Fligelstone¹⁶, Mohammed Zubair¹⁷, Justin C. Mason^{18,†}, Christopher P. Denton ¹⁹, Ariane L Herrick ^{15,20,*}

¹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK

²Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK

³Department of Rheumatology, Royal United Hospitals Bath NHS Trust, Bath, UK

⁴Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁵Department of Rheumatology, Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK

⁶Department of Rheumatology, Ninewells Hospital and Medical School, Dundee, UK

⁷Department of Rheumatology, Dudley Group NHSFT, Dudley, UK

⁸Rheumatology Department, North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bristol, UK

⁹Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

¹⁰Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

¹¹Department of Rheumatology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

¹²NIHR Biomedical Research Centre and Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

¹³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, UK

¹⁴Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK

¹⁵NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

¹⁶Royal Free Hospital, London, UK

¹⁷Research Governance and Integrity, The University of Manchester, Manchester, UK

¹⁸National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK

¹⁹Centre for Rheumatology, UCL Division of Medicine, Royal Free Campus, London, UK

²⁰Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

*Correspondence to: Ariane Herrick, Centre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester M13 9PT, UK.

E-mail: ariane.herrick@manchester.ac.uk

[†]Deceased. The authors are very grateful to the late Professor Mason for his contributions to PRedSS including his chairing of the PRedSS Trial Steering committee.

Abstract

Objectives: Although the painful and disabling features of early diffuse cutaneous SSc (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate-dose prednisolone in early dcSSc.

Methods: PRedSS set out as a Phase II, multicentre, double-blind randomized controlled trial, converted to open-label during the Covid-19 pandemic. Patients were randomized to receive either prednisolone (~0.3 mg/kg) or matching placebo (or no treatment during open-label) for 6 months. Co-primary endpoints were the HAQ Disability Index (HAQ-DI) and modified Rodnan skin score (mRSS) at 3 months. Over 20 secondary endpoints included patient reported outcome measures reflecting pain, itch, fatigue, anxiety and depression, and helplessness. Target recruitment was 72 patients.

Results: Thirty-five patients were randomized (17 prednisolone, 18 placebo/control). The adjusted mean difference between treatment groups at 3 months in HAQ-DI score was -0.10 (97.5% CI: -0.29, 0.10), $P=0.254$, and in mRSS -3.90 (97.5% CI: -8.83, 1.03), $P=0.070$, both favouring prednisolone but not significantly. Patients in the prednisolone group experienced significantly less pain ($P=0.027$), anxiety ($P=0.018$) and helplessness ($P=0.040$) than control patients at 3 months. There were no renal crises, but sample size was small.

Conclusion: PRedSS was terminated early primarily due to the Covid-19 pandemic, and so was underpowered. Therefore, interpretation must be cautious and results considered inconclusive, indicating the need for a further randomized trial.

Trial registration: ClinicalTrials.gov, <https://clinicaltrials.gov>, NCT03708718.

Keywords: SSc, pain, disability, randomized controlled trial, corticosteroids

Received: 17 August 2022. Accepted: 26 December 2022

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com

Rheumatology key messages

- Whether or not corticosteroids should be prescribed in early dcSSc is highly contentious.
- PRedSS is the first randomized controlled trial of moderate dose corticosteroids in early dcSSc.
- PRedSS's inconclusive results indicate the need for a further randomized controlled trial.

Introduction

Early diffuse cutaneous SSc (dcSSc) is painful, disabling and disfiguring because of (often rapidly progressive) widespread skin thickening [1] and musculoskeletal involvement. Recent publications have bench-marked this pain and disability [2, 3], increasing awareness of the need to address quality of life issues as well as survival in patients with early dcSSc.

At present there is no effective disease modifying treatment for early dcSSc. Guidelines advocate immunosuppression [4, 5], which may confer modest benefit [6], and haematopoietic stem cell transplantation may be an option in highly selected cases [7, 8]. A key question is whether corticosteroids should be prescribed. In favour of corticosteroids is that the symptoms that have a major negative impact on the everyday lives of patients with early dcSSc (tight, painful, itchy skin, and loss of function due to contractures and musculoskeletal involvement) have an inflammatory basis [9]. However, corticosteroids are a risk factor for renal crisis [10–12] of which patients with early dcSSc are already at high risk, especially when anti-RNA polymerase III positive [12].

Against this background, the aim of the PRednisolone in early diffuse SSc (PRedSS) trial was to examine safety and efficacy of moderate-dose prednisolone in patients with early dcSSc. Specific objectives were to evaluate whether moderate-dose prednisolone reduced pain and disability, and improved skin score, and whether prednisolone was safe with particular reference to renal function.

Methods

Study design

PRedSS set out as a Phase II, multicentre, double-blind randomized controlled trial (RCT) but was converted to open-label after blinded treatment with prednisolone or placebo became untenable during the Covid-19 pandemic. The trial protocol is described in detail elsewhere [13]. The study was approved by the North West–Greater Manchester South Research Ethics Committee. All participants gave written informed consent.

After a screening visit, patients were assessed at baseline, 6 weeks, 3 months and 6 months. Randomization (ensuring allocation concealment) was 1:1 to either enteric-coated prednisolone or matching placebo capsules (one active capsule = 5 mg prednisolone), stratified by anti-topoisomerase (anti-Scl70) antibody positivity. Stratification for anti-RNA polymerase III positivity (the ideal option) was not feasible because not all participating centres had access to rapid testing for anti-RNA polymerase III.

Patients

Patients from 14 UK centres were recruited. The main inclusion criteria were adults (age >18 years) with early dcSSc (skin involvement extending proximal to the elbow or knee,

or involving trunk and within 3 years of onset of skin thickening). Exclusion criteria are listed in [Supplementary Table S1](#), available at *Rheumatology* online.

Treatment

Patients received, for 6 months, ~0.3 mg/kg of prednisolone or less (or placebo equivalent): weight <50 kg = 10 mg; >50 kg but <60 kg = 15 mg; >60 kg but <80 kg = 20 mg; >80 kg but <100 kg = 25 mg; >100 kg = 30 mg. If a patient experienced adverse effects thought likely related to trial treatment, then the dose could be reduced. Trial treatment was additive to background treatment, including immunosuppressant therapy. A proton pump inhibitor and a calcium and vitamin D supplement were co-prescribed with the trial treatment. At the 6-month (final) visit, the treatment code was broken.

Outcomes

The co-primary outcome measures (examined at 3 months, to maximize patient retention up until the primary end point, and also because any symptomatic improvement in response to prednisolone was likely to occur within a short time frame) were functional ability as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) [14] and the modified Rodnan skin score (mRSS) [15, 16]. The HAQ-DI [15] is self-administered (advantageous in the Covid-19 era) whereas the mRSS involves palpation of the skin by the examining clinician.

Secondary efficacy outcomes and safety outcomes are listed in [Supplementary Table S2](#), available at *Rheumatology* online.

Statistical analysis

This is discussed in full elsewhere [13], including the power calculation, which indicated that 60 patients (30 per arm) would give 82% power. We aimed to recruit 12 more patients allowing for a 17% attrition.

All statistical analyses were conducted on an intention-to-treat basis to include all randomized patients with baseline data and at least one follow-up. Continuous outcomes were analysed using mixed models for repeated measures (MMRM) to assess differences between the treatment arms. Missing data were assumed to be missing at random and handled within the MMRM approach, which remains valid given such a mechanism. Each model included the fixed categorical effects of treatment (prednisolone *vs* placebo), time point (6 weeks, 3 months and 6 months), whether a patient was anti-topoisomerase positive, and baseline score as well as the interactions of all fixed terms with time point. A general unstructured covariance matrix (six parameters) was used for the error terms. The models were fitted using restricted maximum likelihood and employed Kenward–Roger degrees of freedom adjustment [17].

The primary analysis focus was the contrast (adjusted mean difference in HAQ-DI and mRSS scores) between trial arms at 3 months using an adjusted two-tail 2.5% significance level. Secondary outcomes were exploratory in nature, each employing an unadjusted two-tail 5% significance level.

We conducted a sensitivity analysis by repeating the primary analysis for two different periods (i.e. 'pre' and 'during' lockdown) to help determine the extent to which the trial may have been affected by the Covid-19 pandemic.

All statistical analyses were performed using Stata/IC version 15.1, (StataCorp, College Station, TX, USA).

Covid-19 impact on methods

On 23 March 2020 the code was broken on all 11 patients currently on trial treatment (10 of whom were on immunosuppressant therapy and therefore deemed at high risk from Covid-19 if also on prednisolone) and to halt further recruitment. Ten continued on/completed the trial on an open-label basis. Because double-blind prednisolone was not going to be a viable option in the short to medium term, approvals were obtained to re-open PRedSS as an open-label study (11 August 2020). A request for extension funding to continue recruitment was declined. PRedSS closed to recruitment in February 2021.

Results

Patients were recruited into the double-blind RCT between 15 December 2017 and 23 March 2020 or into the open-label phase between 11 August 2020 and 31 January 2021. Twenty-five patients were randomized during the double-blind phase (13 to prednisolone) and 10 during the open-label phase (four to prednisolone). Therefore 17 were randomized to prednisolone and 18 to placebo or to no treatment ('control patients'). [Supplementary Fig. S1](#), available at *Rheumatology* online, shows patient progression through the study. [Supplementary Table S3](#), available at *Rheumatology* online, shows the number of participants and the frequency (%) of missing outcome data.

Baseline characteristics of patients

Baseline characteristics of patients are summarized in [Supplementary Table S4](#), available at *Rheumatology* online. The mean disease duration from onset of skin thickening was 1.7 (s.d. 0.8) years, reflecting an early disease cohort.

Analysis of primary outcome measures—HAQ-DI and mRSS

There was a small but not significant difference between treatment groups in HAQ-DI score at 3 months, after adjustment for baseline score and anti-topoisomerase (mean difference -0.10 at 3 months; 97.5% CI: $-0.29, 0.10$, $P = 0.254$), in favour of the prednisolone group ([Table 1](#)). Although there was no significant difference in mRSS scores between treatment groups (mean difference -3.90 at 3 months, 97.5% CI: $-8.83, 1.03$, $P = 0.070$) ([Table 1](#)), again the estimate favoured prednisolone.

We also tested the interaction treatment-by-time to assess whether treatment effects at 3 months were any different from the treatment effects at either of the other time points (6 weeks, 6 months). Neither the interaction term for the

HAQ-DI nor that for the mRSS was statistically significant ($P = 0.16$ and 0.48 , respectively).

[Supplementary Fig. S2](#), available at *Rheumatology* online, shows the trajectories of the HAQ-DI scores and mRSS for each treatment group. [Fig. 1A and B](#) shows predictive margins derived from the fitted MMRM models. [Supplementary Fig. S2](#) demonstrates how prednisolone and control groups both experienced an improvement in skin thickening between baseline and 6 months, with the prednisolone group starting from a lower baseline.

Sensitivity analyses results for the primary endpoints are shown in [Table 1](#). Results based on the datasets for the different time periods were similar for the HAQ-DI, yielding the same conclusion, i.e. no significant effect of prednisolone on functional ability at 3 months. For mRSS, the treatment effect at 3 months increased from -1.38 to -3.90 when period III (post-lockdown) results were included.

Analysis of secondary outcome measures

Three of the secondary outcomes (VAS pain, the Hospital Anxiety and Depression Scale [HADS] anxiety scale and the 5-item helplessness subscale of the Rheumatology Attitudes Index [RAI]) showed a statistically significant difference between the treatment groups at 3 months at the 5% significant level, all in favour of the prednisolone group ([Table 1](#)). There was also a trend in favour of the Scleroderma Skin Patient Reported Outcome (SSPRO). Trajectories are illustrated in [Fig. 1C–F](#).

The interaction treatment-by-time (6 weeks, 3 months, 6 months) was not significant for any of the secondary outcomes.

Results for digital ulcer count, friction rubs and swollen and tender joint count at 3 months are shown in [Supplementary Table S5](#), available at *Rheumatology* online. Few patients had these on physical examination.

Treatment adherence

Treatment adherence and a description of how this was calculated is given in [Supplementary Data S1](#), available at *Rheumatology* online. During the double-blind phase, 18/25 (72%) adhered to treatment ($\geq 80\%$ treatment adherence with missing information in 5/25 (20%)). During the open-label phase, 3/4 (75%) patients adhered to treatment with missing information in 1/4 (25%).

Adverse events

There were a total of 44 adverse events from 15 participants, 22 in the prednisolone group and 22 in the control group. There were four serious adverse events in two control participants: one patient suffered a myocardial infarction and haematoma secondary to edoxaban, and the other developed pulmonary arterial hypertension and cardiac failure secondary to pulmonary hypertension. There were two cases of new hypertension, both in patients on prednisolone, and two cases of worsening of existing hypertension, both in control participants. There were no cases of scleroderma renal crisis, no serious infections and no new diabetes.

Discussion

PRedSS was a casualty of the Covid-19 pandemic and was halted early. The major limitation of the study was that the

Table 1. Treatment effects of the continuous outcomes at 3 months

Outcome	<i>n</i>	Difference (S.E.) (CI)	<i>P</i> -value	Effect in favour of
Co-primary outcomes^a				
HAQ-DI	34	-0.10 (0.08) (-0.29, 0.10)	0.254	Prednisolone
mRSS	31	-3.90 (2.05) (-8.83, 1.03)	0.070	Prednisolone
Sensitivity analyses^a				
HAQ-DI				
Period I (pre-lockdown)	23	-0.12 (0.14) (-0.48, 0.23)	0.383	Prednisolone
Period II (lockdown)	25	-0.07 (0.11) (-0.33, 0.19)	0.506	Prednisolone
Period III (post-lockdown)	34	-0.10 (0.08) (-0.29, 0.10)	0.254	Prednisolone
mRSS				
Period I (pre-lockdown)	23	-1.38 (2.41) (-7.41, 4.66)	0.576	Prednisolone
Period II (lockdown)	23	-1.38 (2.41) (-7.41, 4.66)	0.576	Prednisolone
Period III (post-lockdown)	31	-3.90 (2.05) (-8.83, 1.03)	0.070	Prednisolone
Secondary outcomes^b				
SHAQ VAS scales				
Pain	34	-0.49 (0.21) (-0.93, -0.06)	0.027	Prednisolone
Intestinal problems	34	0.38 (0.24) (-0.11, 0.87)	0.121	Control
Breathing	34	-0.00 (0.24) (-0.48, 0.48)	0.995	Prednisolone
Raynaud's phenomenon	34	-0.12 (0.31) (-0.75, 0.51)	0.704	Prednisolone
Finger ulcers	33	-0.13 (0.21) (-0.55, 0.30)	0.550	Prednisolone
Overall disease activity	32	-0.16 (0.24) (-0.65, 0.33)	0.505	Prednisolone
11 point scleroderma functional index	34	-0.41 (1.84) (-4.17, 3.36)	0.827	Prednisolone
SSPRO	27	-12.66 (6.26) (-25.59, 0.26)	0.055	Prednisolone
5-D Itch	22	-1.17 (1.74) (-4.80, 2.46)	0.509	Prednisolone
CHFS	32	-0.21 (2.86) (-6.08, 5.66)	0.942	Prednisolone
FACIT	34	4.22 (3.00) (-1.91, 10.34)	0.170	Prednisolone
HADS: anxiety	34	-2.05 (0.82) (-3.73, -0.37)	0.018	Prednisolone
HADS: depression	34	0.91 (0.69) (-0.50, 2.32)	0.197	Control
RAI: helplessness	34	-1.54 (0.72) (-3.01, -0.07)	0.040	Prednisolone
SF-36: physical component	34	1.83 (1.89) (-2.04, 5.69)	0.343	Prednisolone
SF-36: mental component	34	-1.65 (3.55) (-8.91, 5.62)	0.647	Control
EQ 5D 3L: health utility	34	0.15 (0.09) (-0.03, 0.32)	0.098	Prednisolone
EQ 5D 3L health state: VAS	34	5.31 (7.06) (-9.14, 19.75)	0.459	Prednisolone
Patient global assessment	31	0.84 (0.68) (-0.56, 2.24)	0.230	Prednisolone
Physician global assessment	32	-0.63 (0.73) (-2.13, 0.87)	0.396	Prednisolone

Results generated from the MMRM models adjusting for anti-topoisomerase and baseline values of the associated outcome. Difference = Prednisolone – Control.

^a Difference (S.E.) is shown with 97.5% CI.

^b Difference (S.E.) is shown with 95% CI.

P-values of <0.025 are statistically significant for the co-primary outcomes. *P*-values of <0.05 are statistically significant for the secondary outcomes. Sensitivity analyses time periods: period I includes all available data up to the 22 March 2020, just before the recruitment was halted due to a national lockdown. Period II includes all available data from the start of the trial until the 11 August 2020 when trial recruitment resumed following the national lockdown. Period III is the primary analysis and includes all available data for the 35 randomized participants (i.e. pre-lockdown, lockdown and post-lockdown data). CHFS: Cochin Hand Function Scale; FACIT: Functional Assessment of Chronic Illness Therapy; HADS: Hospital Anxiety and Depression Scale; HAQ-DI: HAQ Disability Index; mRSS: modified Rodnan skin score; RAI: Rheumatology Attitudes Index; SF-36: 36-item Short Form Survey; SHAQ: Scleroderma Health assessment Questionnaire; SSPRO: Scleroderma Skin Patient Reported Outcome; VAS: visual analogue scale.

35 patients recruited (of whom 10 were open-label) fell short of the target of 72, rendering results inconclusive.

At 3 months, trajectories for both co-primary endpoints (the HAQ-DI and the mRSS) favoured prednisolone, although there were no statistically significant differences between groups and the estimated benefit of prednisolone on functional ability, as gauged by the adjusted mean HAQ-DI at 3 months, was small (-0.10). The assessment of the mRSS was hampered with the move away from face-to-face follow-up assessments necessitated by the COVID-19 pandemic, and open-label assessments had the potential of observer bias. Bearing in mind these limitations, the estimated benefit of prednisolone on the adjusted mean mRSS at 3 months was moderate (-3.9) with a minimally clinically important difference of -5 [18] lying within the confidence interval.

The large number of secondary outcomes (over 20) means that interpretation of these results should be even more cautious. However, it is worth noting the benefits of prednisolone over placebo at 3 months in pain and in helplessness (and also

in anxiety). Treatment with prednisolone appeared safe. Specifically there were no renal crises, although patient numbers were small and it is also possible that longer durations of prednisolone therapy might increase renal crisis risk.

PRedSS provides valuable information to take forward to a future clinical trial. First, a double-blind trial of prednisolone is complex, due to the need to adjust corticosteroid dose during intercurrent illness and therefore increasing the likelihood of code-breaks, particularly during the Covid-19 era. Second, remote visits are feasible, reducing the need for patients to travel to hospital (a major advantage during the Covid-19 era) because (i) we have shown that the patient reported outcome measures in PRedSS were acceptable to patients in terms of 'questionnaire burden' and (ii) skin score can now be self-assessed through development of the Patient self-Assessment of Skin Thickness in Upper Limb (PASTUL) questionnaire [19]. Third, our experience with PRedSS will inform power calculations and likely recruitment rates for a future study. And so although PRedSS has not provided a definitive answer




Figure 1. Primary and secondary outcomes. Predictive margins (mean scores) at follow-up times with 97.5% CIs for the HAQ-DI and mRSS and 95% CIs for the remaining outcomes. These are predictions for a set of cases 'like' (in terms of baseline and anti-topoisomerase values) the combined sample if all were treated with the intervention or all as control respectively. The combined group baseline mean scores are also displayed. HADS: Hospital Anxiety and Depression Scale; HAQ-DI: HAQ Disability Index; mRSS: modified Rodnan skin score; RAI: Rheumatology Attitudes Index; SSPRO: Scleroderma Skin Patient Reported Outcome; VAS: visual analogue scale

as to whether or not corticosteroids should be prescribed in patients with early dcSSc, it provides critical insights for future studies addressing this important clinical question, and perhaps also provides support for the view of many clinicians that it is not unreasonable to prescribe short-term moderate dose prednisolone for symptom control, always remembering the importance of careful monitoring of blood pressure and renal function.

Supplementary material

Supplementary material is available at *Rheumatology* online.

Data availability

De-identified participant data and a data dictionary (as well as the study protocol and the statistical analysis plan) will be available to qualified researchers 6 months after publication, after approval of a proposal by the sponsor, and the signing of a data sharing access agreement with the trial sponsor.

Funding

This work was supported by Versus Arthritis (grant number 21021).

Disclosure statement: J.D.P. has received speaker fees from Janssen and consultancy fees from Janssen, Astra Zeneca, Permeatus Inc., Boehringer-Ingelheim and Sojournix Pharma. F.H. has received research grants from BMS, Alexion and Lilly; consultancy with Roche. P.L. has received consultancy fees from Pfizer and research funding from Vifor Pharma. H.G. has received speaker fees from Boehringer Ingelheim. M.A. has received consultancy fees from Gilead, Nordic pharma, speaker fees from Janssen and sponsorship to attend meetings from GSK, Eli Lilly, Roche and AstraZeneca. B.G. is the Chair of NHS England's Clinical Reference Group for Specialized Rheumatology. C.P.D. reports grants and personal fees from Acceleron, Janssen, Arxx Therapeutics, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, GlaxoSmithKline, Horizon, Roche, and Abbvie; all outside the submitted work. A.L.H. has received consultancy fees from Arena, Boehringer-Ingelheim, Camurus, CSL Behring and Gesynta Pharma, speaker fees from Actelion and Janssen, and research funding from Actelion and Gesynta Pharma.

Acknowledgements

PRedSS was funded by Versus Arthritis. The study was supported by the United Kingdom Clinical Research Collaboration-registered King's Clinical Trials Unit at King's Health Partners, which is part funded by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR Evaluation, Trials and Studies Coordinating Centre. We are grateful to the members of the independent data monitoring committee: Lorraine Harper, Luc Mouthon and Melissa Bucknall. Also, to Rachel Jones and Svetlana Tishkovskaya for their contributions as members of the Trial Steering Committee. We are also grateful to Dr Robert Lafyatis for allowing us to use SSPRO and to Dr Marlyn Mayo for permission to use the 5-D Itch Questionnaire.

References

- Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. *Nat Rev Rheumatol* 2022;18:276–85.
- Peytrignet S, Denton CP, Lunt M *et al.* Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. *Rheumatology* 2018; 57:370–81.
- Zheng B, Nevskaya T, Baxter CA *et al.*; Canadian Scleroderma Research Group. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. *Rheumatology* 2020;59:398–406.
- Denton CP, Hughes M, Gak N *et al.*; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of systemic sclerosis. *Rheumatology* 2016;55: 1906–10.
- Kowal-Bielecka O, Fransen J, Avouac J *et al.*; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017;76:1327–39.
- Herrick AK, Pan X, Peytrignet S *et al.* Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). *Ann Rheum Dis* 2017;76:1207–18.
- Van Laar JM, Farge D, Sont JK *et al.*; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA* 2014;311: 2490–8.
- Sullivan KM, Goldmuntz EA, Keyes-Elstein L *et al.* Myeloablative autologous stem-cell transplantation for severe scleroderma. *N Eng J Med* 2018;378:35–47.
- Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L. Is there today a place for corticosteroids in the treatment of scleroderma? *Autoimmun Rev* 2019;18:102403.
- Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. *Arthritis Rheum* 1998;41:1613–9.
- Guillevin L, Berezne A, Seror R *et al.* Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. *Rheumatology* 2012;51:460–7.
- Hoa S, Stern EP, Denton CP, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group, Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Towards developing criteria for scleroderma renal crisis: a scoping review. *Autoimmun Rev* 2017;16:407–15.
- Herrick AL, Griffiths-Jones DJ, Ryder WD, Mason JC, Denton CP. Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). *J Scleroderma Rel Disord* 2021;6: 146–53.
- Steen VD, Medsger TA. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. *Arthritis Rheum* 1997;40:1984–91.
- Khanna D, Furst DE, Clements PJ *et al.* Standardisation of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *J Scleroderma Relat Disord* 2017;2:11–8.
- Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. *Rheumatology* 2008;47(Suppl 5):v29–30.
- Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrics* 1997;53: 983–97.
- Khanna D, Clements PJ, Volkman ER *et al.* Minimally clinically important differences for the modified Rodnan skin score: result from the Scleroderma Lung Studies (SLS-I and SLS-II). *Arthritis Res Ther* 2019;21:23.
- Spierings J, Ong V, Denton CP. PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. *Ann Rheum Dis* 2021;80:819–20.